VYNDAQEL 20 mg, soft capsule capsule
Active ingredients: Tafamidis, Tafamidis meglumine
Commercialized according to BDPMDispensing in France: Prescription only
Soft capsulecapsuleorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VYNDAQEL 20 mg, capsule molle
- Pharmaceutical form
- capsule molle
- Route of administration
- orale
- Presentation description
- plaquettes PVC polyamide aluminium PVC-Aluminium de 30 x 1 capsules (conditionnement unitaire)
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 30 Jan 2012
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
66376626CIP72182459CIP133400921824599Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TAFAMIDIS MÉGLUMINEcapsule | 20 mg · une capsule | SA |
| TAFAMIDIScapsule | 12,2 mg · une capsule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.